| pubmed-article:12355478 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12355478 | lifeskim:mentions | umls-concept:C0003873 | lld:lifeskim |
| pubmed-article:12355478 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:12355478 | lifeskim:mentions | umls-concept:C0449258 | lld:lifeskim |
| pubmed-article:12355478 | lifeskim:mentions | umls-concept:C0750572 | lld:lifeskim |
| pubmed-article:12355478 | lifeskim:mentions | umls-concept:C0010186 | lld:lifeskim |
| pubmed-article:12355478 | lifeskim:mentions | umls-concept:C0870071 | lld:lifeskim |
| pubmed-article:12355478 | lifeskim:mentions | umls-concept:C0220812 | lld:lifeskim |
| pubmed-article:12355478 | lifeskim:mentions | umls-concept:C0686907 | lld:lifeskim |
| pubmed-article:12355478 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:12355478 | pubmed:dateCreated | 2002-9-30 | lld:pubmed |
| pubmed-article:12355478 | pubmed:abstractText | Two simulation models were developed to analyze the cost-effectiveness of new treatments that affect the progression of rheumatoid arthritis (RA). | lld:pubmed |
| pubmed-article:12355478 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12355478 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12355478 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:12355478 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12355478 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:12355478 | pubmed:issn | 0004-3591 | lld:pubmed |
| pubmed-article:12355478 | pubmed:author | pubmed-author:LindgrenPeter... | lld:pubmed |
| pubmed-article:12355478 | pubmed:author | pubmed-author:EberhardtKers... | lld:pubmed |
| pubmed-article:12355478 | pubmed:author | pubmed-author:JönssonLinusL | lld:pubmed |
| pubmed-article:12355478 | pubmed:author | pubmed-author:KobeltGiselaG | lld:pubmed |
| pubmed-article:12355478 | pubmed:author | pubmed-author:YoungAdamA | lld:pubmed |
| pubmed-article:12355478 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12355478 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:12355478 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12355478 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12355478 | pubmed:pagination | 2310-9 | lld:pubmed |
| pubmed-article:12355478 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:12355478 | pubmed:meshHeading | pubmed-meshheading:12355478... | lld:pubmed |
| pubmed-article:12355478 | pubmed:meshHeading | pubmed-meshheading:12355478... | lld:pubmed |
| pubmed-article:12355478 | pubmed:meshHeading | pubmed-meshheading:12355478... | lld:pubmed |
| pubmed-article:12355478 | pubmed:meshHeading | pubmed-meshheading:12355478... | lld:pubmed |
| pubmed-article:12355478 | pubmed:meshHeading | pubmed-meshheading:12355478... | lld:pubmed |
| pubmed-article:12355478 | pubmed:meshHeading | pubmed-meshheading:12355478... | lld:pubmed |
| pubmed-article:12355478 | pubmed:meshHeading | pubmed-meshheading:12355478... | lld:pubmed |
| pubmed-article:12355478 | pubmed:meshHeading | pubmed-meshheading:12355478... | lld:pubmed |
| pubmed-article:12355478 | pubmed:meshHeading | pubmed-meshheading:12355478... | lld:pubmed |
| pubmed-article:12355478 | pubmed:meshHeading | pubmed-meshheading:12355478... | lld:pubmed |
| pubmed-article:12355478 | pubmed:meshHeading | pubmed-meshheading:12355478... | lld:pubmed |
| pubmed-article:12355478 | pubmed:meshHeading | pubmed-meshheading:12355478... | lld:pubmed |
| pubmed-article:12355478 | pubmed:meshHeading | pubmed-meshheading:12355478... | lld:pubmed |
| pubmed-article:12355478 | pubmed:meshHeading | pubmed-meshheading:12355478... | lld:pubmed |
| pubmed-article:12355478 | pubmed:meshHeading | pubmed-meshheading:12355478... | lld:pubmed |
| pubmed-article:12355478 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12355478 | pubmed:articleTitle | Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. | lld:pubmed |
| pubmed-article:12355478 | pubmed:affiliation | Health Dynamics International, Speracedes, France. gisela.kobelt@easynet.fr | lld:pubmed |
| pubmed-article:12355478 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12355478 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12355478 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12355478 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12355478 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12355478 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12355478 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12355478 | lld:pubmed |
